DATA MONITORING

$0U10FY2001CANIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 39055377 Paper 37539667 Paper 36050448 Paper 35859079 Paper 34804634 Paper 33154022 Paper 32923882 Paper 32504284 Paper 31802506 Paper 31213748 Paper 30775161 Paper 29848457 Paper 29649081 Paper 29530935 Paper 29313954 Paper 29164377 Paper 29138761 Paper 29044496 Paper 28939223 Paper 28921241 Paper 28917648 Paper 28786105 Paper 28700816 Paper 28691116 Paper 28691057 Paper 28687377 Paper 28649983 Paper 28646344 Paper 28620884 Paper 28533226 Paper 28493308 Paper 28402581 Paper 28384065 Paper 28375706 Paper 28323331 Paper 28280603 Paper 28262692 Paper 28239505 Paper 28089762 Paper 28006055 Paper 27943153 Paper 27881709 Paper 27590208 Paper 27534963 Paper 27478689 Paper 27468630 Paper 27458945 Paper 27374464 Paper 27365012 Paper 27302508 Paper 27197192 Paper 27098150 Paper 27075674 Paper 27060850 Paper 27050206 Paper 26858337 Paper 26811529 Paper 26598744 Paper 26578722 Paper 26526218 Paper 26429296 Paper 26392097 Paper 26381420 Paper 26371148 Paper 26282635 Paper 26187617 Paper 26160882 Paper 26138065 Paper 26134227 Paper 26114161 Paper 26113580 Paper 26056183 Paper 26035698 Paper 25975718 Paper 25930719 Paper 25749740 Paper 25717423 Paper 25697217 Paper 25589620 Paper 25526733 Paper 25519478 Paper 25513417 Paper 25510254 Paper 25482023 Paper 25423327 Paper 25422488 Paper 25359867 Paper 25349302 Paper 25332249 Paper 25305506 Paper 25247339 Paper 25157767 Paper 25117820 Paper 25092775 Paper 25074878 Paper 25071121 Paper 25043153 Paper 24989892 Paper 24980603 Paper 24934787

Abstract

The NCCTG Data Monitoring Committee reviews all phase III cancer treatment and cancer control trials coordinated by NCCTG. The primary functions of the Committee are: a) to assure safety of the treatment regimens, b) to examine efficacy results and determine whether or not the trial should be continued, modified, or discontinued, c) to review changes in study design in order to promote scientific integrity of the trial, d) to review accrual information in order to assure that the trial will yield meaningful results, and e) to review requests for release of data to investigators prior to general release as specified in the trial design.

View original record on NIH RePORTER →